{"id":19192,"date":"2023-04-28T20:02:00","date_gmt":"2023-04-28T12:02:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19192"},"modified":"2024-12-21T20:08:09","modified_gmt":"2024-12-21T12:08:09","slug":"reforgene-medicine-secures-pre-series-b-funding-to-advance-thalassemia-gene-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19192","title":{"rendered":"Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy"},"content":{"rendered":"\n<p>Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of renminbi in a Pre-Series B financing round. The round was led by Yuexiu Industrial Fund, with participation from other notable investors including Yuanying Venture Capital, Shanfeng Venture Capital, Emerging Fund, Ganyue Investment, Guoju Venture Capital, China Everbright, Alwin Capital, and BioTrack Capital. The funds raised will be directed towards accelerating clinical studies for a thalassemia therapy, as well as research and development of gene therapy and underlying technological innovations.<\/p>\n\n\n\n<p><strong>Clinical Progress and Milestones for Reforgene<\/strong><br>Founded in 2019, Reforgene Medicine obtained tacit clinical trial approval for its \u03b2-thalassemia drug RM-001 in China in November 2022, with the Phase I study currently underway. The early clinical studies have shown promising results, with all thalassemia patients treated showing complete cure and a return to good health, having resumed their normal lives.<\/p>\n\n\n\n<p><strong>The Impact of Reforgene&#8217;s Gene Therapy<\/strong><br>Reforgene&#8217;s gene editing therapies hold significant potential in the field of genetic medicine, particularly for diseases like thalassemia. The successful fundraising and clinical progress indicate a strong foundation for the company to further develop its therapies and contribute to medical advancements in gene editing and therapeutics.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,24,1217],"class_list":["post-19192","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-finance","tag-rare-orphan-disease-drugs","tag-reforgene-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of renminbi in a Pre-Series B financing round. The round was led by Yuexiu Industrial Fund, with participation from other notable investors including Yuanying Venture Capital, Shanfeng Venture Capital, Emerging Fund, Ganyue Investment, Guoju Venture Capital, China Everbright, Alwin Capital, and BioTrack Capital. The funds raised will be directed towards accelerating clinical studies for a thalassemia therapy, as well as research and development of gene therapy and underlying technological innovations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19192\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19192\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-28T12:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-21T12:08:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19192#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19192\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy\",\"datePublished\":\"2023-04-28T12:02:00+00:00\",\"dateModified\":\"2024-12-21T12:08:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19192\"},\"wordCount\":211,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finance\",\"Rare \\\/ orphan disease drugs\",\"Reforgene Medicine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19192#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19192\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19192\",\"name\":\"Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-28T12:02:00+00:00\",\"dateModified\":\"2024-12-21T12:08:09+00:00\",\"description\":\"Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of renminbi in a Pre-Series B financing round. The round was led by Yuexiu Industrial Fund, with participation from other notable investors including Yuanying Venture Capital, Shanfeng Venture Capital, Emerging Fund, Ganyue Investment, Guoju Venture Capital, China Everbright, Alwin Capital, and BioTrack Capital. The funds raised will be directed towards accelerating clinical studies for a thalassemia therapy, as well as research and development of gene therapy and underlying technological innovations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19192#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19192\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19192#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of renminbi in a Pre-Series B financing round. The round was led by Yuexiu Industrial Fund, with participation from other notable investors including Yuanying Venture Capital, Shanfeng Venture Capital, Emerging Fund, Ganyue Investment, Guoju Venture Capital, China Everbright, Alwin Capital, and BioTrack Capital. The funds raised will be directed towards accelerating clinical studies for a thalassemia therapy, as well as research and development of gene therapy and underlying technological innovations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19192","og_locale":"en_US","og_type":"article","og_title":"Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19192","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-28T12:02:00+00:00","article_modified_time":"2024-12-21T12:08:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19192#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19192"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy","datePublished":"2023-04-28T12:02:00+00:00","dateModified":"2024-12-21T12:08:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19192"},"wordCount":211,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finance","Rare \/ orphan disease drugs","Reforgene Medicine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19192#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19192","url":"https:\/\/flcube.com\/?p=19192","name":"Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-28T12:02:00+00:00","dateModified":"2024-12-21T12:08:09+00:00","description":"Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of renminbi in a Pre-Series B financing round. The round was led by Yuexiu Industrial Fund, with participation from other notable investors including Yuanying Venture Capital, Shanfeng Venture Capital, Emerging Fund, Ganyue Investment, Guoju Venture Capital, China Everbright, Alwin Capital, and BioTrack Capital. The funds raised will be directed towards accelerating clinical studies for a thalassemia therapy, as well as research and development of gene therapy and underlying technological innovations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19192#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19192"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19192#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19192"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19192\/revisions"}],"predecessor-version":[{"id":19194,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19192\/revisions\/19194"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}